跳至主要内容
临床试验/ACTRN12624000345583
ACTRN12624000345583招募中2 期

Testosterone treatment for the management of fatigue in ambulatory patients with advanced cancer: A pilot feasibility double-blind placebo-controlled study

niversity of Technology Sydney0 个研究点目标入组 26 人开始时间: 2024年3月26日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
26

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Adult men and women with advanced cancer, solid organ or haematopoietic malignancy
  • 18 years or older
  • The Palliative Care Outcome Collaboration (PCOC) Symptom Assessment Score (SAS) of 3 or greater for fatigue
  • Australia - modified Karnofsky Performance Status Palliative Score of 40 or above
  • Able to give informed consent as determined by the treating clinician
  • Able to complete study procedures and comply with study procedures
  • No indication of primary hypogonadism on the completion of the screening reproductive function questionnaire

排除标准

  • Advanced prostate carcinoma, or current diagnosis of prostate carcinoma receiving active hormonal therapy.
  • Baseline erythrocytosis (haematocrit >50%)
  • Primary male hypogonadism
  • Previous adverse reaction to Testosterone Treatment
  • Pregnant or breastfeeding
  • AKPS of 30 or below.
  • Patients with advanced breast carcinoma if the treating Oncologist objects
  • Allergy or hypersensitivity to Almond oil or tree nuts.
  • Unable to give informed consent.

研究者

发起方
niversity of Technology Sydney

相似试验